Development of drugs for gastrointestinal motor disorders: translating science to clinical need.
about
Profile of acotiamide in the treatment of functional dyspepsiaMaytenus erythroxylon Reissek (Celastraceae) ethanol extract presents antidiarrheal activity via antimotility and antisecretory mechanisms.Constipation-predominant irritable bowel syndrome: a review of current and emerging drug therapies.The PharmWatch programme: challenges to engaging the community pharmacists in Jamaica.Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disordersGhrelin and motilin receptor agonists: time to introduce bias into drug design.Challenges and prospects for pharmacotherapy in functional gastrointestinal disorders.The investigational drug camicinal for the treatment of gastroparesis.The effects of camicinal, a novel motilin agonist, on gastro-esophageal function in healthy humans-a randomized placebo controlled trial.Ion channelopathies in functional GI disorders.The antibiotic azithromycin is a motilin receptor agonist in human stomach: comparison with erythromycin.Linaclotide - a secretagogue and antihyperalgesic agent - what next?The hungry stomach: physiology, disease, and drug development opportunities.The pharmacodynamics, safety and pharmacokinetics of single doses of the motilin agonist, camicinal, in type 1 diabetes mellitus with slow gastric emptying.Motilin: towards a new understanding of the gastrointestinal neuropharmacology and therapeutic use of motilin receptor agonists.The enteric nervous system and neurogastroenterology.Ghrelin and motilin receptors as drug targets for gastrointestinal disorders.Neostigmine-induced contraction and nitric oxide-induced relaxation of isolated ileum from STZ diabetic guinea pigs.Efficacy and safety of Xiangsha Liujunzi granules for functional dyspepsia: A multi-center randomized double-blind placebo-controlled clinical studyRegional differences in neostigmine-induced contraction and relaxation of stomach from diabetic guinea pig.Colonic Transit Time and Gut Peptides in Adult Patients with Slow and Normal Colonic Transit Constipation.The mechanism of enhanced defecation caused by the ghrelin receptor agonist, ulimorelin.GSK962040: a small molecule motilin receptor agonist which increases gastrointestinal motility in conscious dogs.The novel, potent and highly selective 5-HT4 receptor agonist YH12852 significantly improves both upper and lower gastrointestinal motility.Effect of TZP-201, a novel motilin receptor antagonist, in the colon of the musk shrew (Suncus murinus).Diabetes and the Esophagus.A History of Drug Discovery for Treatment of Nausea and Vomiting and the Implications for Future ResearchPeptide YY3-36 and glucagon-like peptide-1 in functional dyspepsia. Secretion and role in symptom generation
P2860
Q26751143-F1A4EE12-1883-4BDD-853E-53A6E9E41675Q33843434-F4C6A6C7-B6D2-418C-B11F-678625D34243Q33958710-BA31B422-3C28-4717-9EEB-404A4FA91319Q34078477-ED8383D8-97DB-4BFC-9681-BFC089714066Q34166903-1CA9C367-FB9D-4AC6-9B2E-AB2545E1FA29Q34398651-35358AB0-7EF0-498A-869A-18154872B553Q34409219-1903D981-9CC5-4BAC-B266-64866D4D6B63Q34444648-B5BF3277-04EF-47E8-84F4-6E4C4F4B1DCCQ34493046-E35C1ED2-DB1C-44FC-BD16-A884F34D2826Q34537076-CFC7D1DC-97B8-4006-AA5B-F5B12558E662Q34645793-D12A85DB-60D9-4A2B-AC29-417C3345B2E7Q34686723-E6194BE8-D196-437F-AD38-8E5D2D9E1C31Q35215647-C994E8AA-9E99-47DB-BBBE-DF000700FED7Q36903406-1931552B-4DF8-4A99-A578-2FB258787DDCQ37337819-9763DBD6-65A8-4C6E-B11E-3C83D7EF7C63Q37990818-298FDEEA-B62D-4A9D-A9F8-831ED84B4069Q38590705-986C83CB-AA44-4D88-9263-FC36B5C2205FQ38977759-1642529F-2A9F-41E1-B402-24C2B0E41315Q41426473-9C33EF71-8267-414C-B03F-4F46CEAFF862Q42559281-DFACB73F-27C4-4E98-ACC4-312DC144C052Q42730653-71FB5BA8-4DAD-433A-A1A4-9E1AD1AEF692Q43309782-AF976C87-E55C-45C1-990C-9AE9447F9B33Q43333422-D555C994-F1C7-4E58-B7D9-A356C3AC0142Q43366415-D3D2C254-5439-4400-9DE5-A15EC49DADE0Q46119494-F036A636-DF8B-49CC-9D1D-1EFB24824C76Q50075786-86CD89C0-5B80-47FE-8A74-D2D67104A7A9Q57161235-3C973D82-4C60-4585-BA81-A3DE8CC3433FQ58447360-57F4DDCD-F720-4A68-B5B2-8880DB3D8A33
P2860
Development of drugs for gastrointestinal motor disorders: translating science to clinical need.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Development of drugs for gastr ...... ting science to clinical need.
@en
Development of drugs for gastr ...... ting science to clinical need.
@nl
type
label
Development of drugs for gastr ...... ting science to clinical need.
@en
Development of drugs for gastr ...... ting science to clinical need.
@nl
prefLabel
Development of drugs for gastr ...... ting science to clinical need.
@en
Development of drugs for gastr ...... ting science to clinical need.
@nl
P2860
P1476
Development of drugs for gastr ...... ting science to clinical need.
@en
P2093
D H Alpers
G J Sanger
P2860
P304
P356
10.1111/J.1365-2982.2008.01084.X
P577
2008-03-01T00:00:00Z